Introduction
============

Neurodegenerative diseases affect millions of people worldwide and have become the most pressing problems in developed countries. A broad range of neurodegenerative disorders, including amyotrophic lateral sclerosis, Parkinson\'s, Alzheimer\'s, Huntington\'s, and glaucoma, are usually characterized by neuronal damage [@B1], [@B2]. They have several common pathological features, such as oxidative stress, inflammation, and hypometabolism [@B3]. As the extension of central nervous system (CNS), the retina displays many similarities to the brain and spinal cord in terms of anatomy, functionality, response to insult, and immunology [@B4]. Moreover, several well-defined neurodegenerative conditions that affect the brain and spinal cord have manifestations in the eye [@B5]. Thus, clarifying the mechanism of retinal neurodegeneration would provide novel insight into the pathogenesis of other neurodegenerative disease [@B6].

Glaucoma is a retinal neurodegenerative disease characterized by progressive gradual loss of retinal ganglion cells (RGCs) and axons [@B7]. The risk factors, including intraocular hypertension, age, vascular dysfunction, corneal thickness and ethnic origin, are tightly associated with the pathogenesis of glaucoma [@B8]. Current methods for glaucoma treatment mainly include surgery and pharmaceuticals. These methods could partially delay the progression of glaucoma and rescue visual field and RGC survival. Stem cell transplantation is beneficial for several retinal neurodegenerative diseases. Previous study has found the transdifferentiation of human periodontal ligament-derived stem cells into functional retinal ganglion-like cells, and identified miR-132, VEGF and PTEN as key regulators in retinal fate determination of human adult stem cells [@B9]. Intravitreal transplantation of mesenchymal stem cells (MSCs) has also been shown to be a neuroprotective therapy for glaucoma in an animal model [@B10]. Reducing intraocular pressure is still the major therapeutic strategy for glaucoma. However, despite effective medical and surgical therapies to reduce intraocular pressure, progressive vision loss is common [@B11], [@B12]. Thus, further study is still required to clarify the precise mechanism of retinal neurodegeneration in glaucoma.

Circular RNAs (circRNAs) are a class of endogenous RNAs characterized by covalently closed continuous loop structures. They are highly abundant, conserved, and dynamically expressed in the CNS [@B13], [@B14]. circRNAs regulate gene expression by acting as microRNA sponges, nuclear transcriptional regulators, protein sponges, protein scaffolds, or by showing translation potentials [@B15], [@B16]. Accumulating studies have revealed that several circRNAs are dysregulated in many neurodegenerative diseases [@B13], [@B17], [@B18]. However, the role of circRNA in retinal neurodegenerative diseases, especially in glaucoma, is still unclear.

cZNF609 has been found to be expressed in neurons and endothelial cells [@B14], [@B19]. It is an important regulator of tumorigenesis, myogenesis, and vascular dysfunction [@B20]-[@B22]. We have shown that cZNF609 is involved in ischemia-induced retinal vascular dysfunction [@B22]. Blood vessels and nerves are two important channels in vivo and usually share the common regulators of differentiation, growth, and navigation [@B23], [@B24]. We speculated that cZNF609 also plays an important role in retinal neurodegeneration. In this study, we investigated the expression pattern of cZNF609 and the role of cZNF609 in retinal neurodegeneration induced by glaucoma.

Methods
=======

Ethics statement
----------------

All animal experiments were performed according to the guidelines of the Care and Use of Laboratory Animals (published by National Institutes of Health) and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The animal experiments were also approved by the Animal Care and Use Committee of Eye & ENT Hospital.

Episcleral vein ligation-induced glaucoma model
-----------------------------------------------

Sprague-Dawley (SD, male, 200-250 g) rats were used for building the glaucoma model through the ligation of three episcleral veins. In brief, the rats were anesthetized by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (75 mg/kg) mixture before surgery. The conjunctiva and Tenon\'s capsule of the left eyes were incised to expose the episcleral veins. Each vein was isolated from the surrounding tissue, ligated with 10-0 nylon suture, and then severed. The control group received the sham surgery expect for the ligation and severance. Intraocular pressure (IOP) was detected using a digital tonometer between 10 AM and 2 PM to avoid the effect of circadian rhythm [@B25].

Microbead injection-induced glaucoma model
------------------------------------------

Sprague-Dawley (SD, male, 200-250 g) rats were used for building the glaucoma model through chamber injection of microbeads. Briefly, the rats were anesthetized by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (75 mg/kg) mixture. During the microbead surgery, one eye was injected with the sterile microbeads, and the control group was injected with an equivalent volume of phosphate-buffered saline (PBS). After the injection, antibiotic drops (0.5% moxifloxacin hydrochloride ophthalmic solution) were placed on each eye. The animal was allowed 24 h recovery before IOP detection. Four weeks after the injection, the second microbead injection was conducted in the above-mentioned animals. IOP was detected using a digital tonometer between 10 AM and 2 PM to avoid the effect of circadian rhythm [@B26].

Immunofluorescence staining
---------------------------

The rat eyes were removed, punctured with a fine gauge needle, and placed in 4% PFA at 4 °C for 12 h. Eyes were then cryoprotected in 30% sucrose for 12 h, embedded in OCT medium (Sakura Finetek). \~10 µm tissue sections were cut using a cryostat (Thermo Scientific) and collected on poly-L-lysine coated slides. Retinal slices were permeabilized with PBS solution containing 0.15% Triton X-100 for 30 min and incubated with 5% bovine serum albumin (BSA) for 1 h to block non-specific antibody binding. Retinal slices were then incubated with the following primary antibodies: TUJ1 (1:300, Abcam), GFAP (1:200, Abcam), GS (1:200, Abcam), Calretinin (1:500, Chemicon), Rhodopsin (1:1,000, Sigma), protein kinase Cα (PKCα, 1:200, Abcam), and Nestin (1:100, Santa Cruz) at 4 °C for 24 h. The slices were washed with PBS and then incubated with the secondary antibody (Invitrogen) overnight at 4 °C. The slides were finally mounted and observed.

Cell culture
------------

Retinal glial cells line (rMC-1) and primary RGCs were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich, St. Louis, MO) at 37 °C and 5% CO~2~.

RNA pull down assay
-------------------

The 3\' end of biotinylated miR-615 or control mimic RNA was transfected into retinal glial cells at a concentration of 30 nM for 24 h. The biotin-coupled RNA complex was pulled down by incubating the cell lysates with streptavidin-coated beads (Life Technologies). The cZNF609 amount in the bound fraction was detected by qRT-PCR.

Statistical analysis
--------------------

All data are expressed as mean ± SEM. The significant difference was determined by two-tailed Student\'s *t* test (two-group comparisons) or one-way ANOVA followed by post hoc Bonferroni test (multi-group comparisons) as appropriate. *P*\<0.05 was considered statistical significance.

Result
======

cZNF609 expression is significantly up-regulated during retinal neurodegeneration
---------------------------------------------------------------------------------

cZNF609 has been reported to be expressed in endothelial cells and tumor cells [@B20], [@B22]. In this study, we first confirmed its expression in rat retinas. The amplified product of cZNF609 was sent for sequencing. Sanger sequencing showed that rat cZNF609 sequence was completely in accordance with the mouse cZNF609 sequence (mmu_circ_0001797), as shown in circBase (**Figure [1](#F1){ref-type="fig"}A**). cZNF609 was resistant to RNase R digestion, whereas linear ZNF609 mRNA was easily degraded (**Figure [1](#F1){ref-type="fig"}B**).

We used the episcleral vein ligation (EVL) method to build a rat model of glaucoma. EVL led to a significant increase in IOP level compared to that of the control group without EVL (**Figure [1](#F1){ref-type="fig"}C**). Moreover, EVL led to a significant increase in cZNF609 expression (**Figure [1](#F1){ref-type="fig"}D**). We also built another rat model of glaucoma by chamber injection of microbeads to impede aqueous outflow. Microbead injection led to a significant elevation in IOP level (20-25 mmHg), which was about two times higher than normal IOP level. The elevation was maintained for another 4 weeks with a second microbead injection, compared to the steady level of 10 mmHg of IOP in the control eyes (**Figure [1](#F1){ref-type="fig"}E**). qRT-PCR assays showed that elevated IOP significantly up-regulated cZNF609 expression level (**Figure [1](#F1){ref-type="fig"}F**). We also revealed that cZNF609 levels in the aqueous humor of glaucomatous rat eyes were higher than those of non-glaucomatous eyes (**Figure [1](#F1){ref-type="fig"}G**).

cZNF609 silencing regulates retinal reactive gliosis and RGC survival in vivo
-----------------------------------------------------------------------------

To investigate the role of cZNF609 in glaucoma-induced retinal neurodegeneration, we designed three different shRNAs for cZNF609 silencing. All of them could significantly decrease cZNF609 expression (**Figure [2](#F2){ref-type="fig"}A**). We selected cZNF609 shRNA1 for cZNF609 silencing because it has the greatest silencing efficiency.

We used the EVL method to establish a rat model of glaucoma. The glaucomatous eyes received an intravitreal injection of scrambled shRNA or cZNF609 shRNA. We employed immunofluorescence staining to determine the effect of cZNF609 silencing on retinal neurodegeneration. Compared with EVL-induced glaucomatous eyes, cZNF609 silencing led to decreased reactive gliosis (decreased GFAP staining) and increased TUJ1 (class III β-tubulin) positive RGCs (**Figure [2](#F2){ref-type="fig"}B-C**). Retinal slices were also immunolabeled with Calretinin (ganglion cells and amacrine cells), Rhodopsin (Rod and cone photoreceptor), and protein kinase Cɑ (PKCɑ; bipolar cells) to determine the effect of cZNF609 silencing on other retinal cell types. Compared with EVL-treated eyes, cZNF609 silencing increased the number of calretinin-labeled cells in the GCL, but did not further affect the number of Calretinin-labeled cells in the INL. We did not detect a staining difference of Rhodopsin and PKCɑ between the scrambled shRNA-injected group and the cZNF609 shRNA-injected group (**Figure [S1](#SM0){ref-type="supplementary-material"}**).

We also used microbead injection-induced glaucomatous rats to determine the effect of cZNF609 silencing on retinal neurodegeneration. We observed a similar scenario in microbead injection-induced glaucomatous retinas as shown in EVL-treated retinas. cZNF609 silencing decreased retinal reactive gliosis, and protected RGCs against glaucoma-induced injury. cZNF609 silencing did not affect the staining signaling of amacrine cells, photoreceptors, or bipolar cells (**Figure [S2](#SM0){ref-type="supplementary-material"}**).

cZNF609 silencing directly regulates Müller cell function but indirectly regulates RGC function*in vitro*
---------------------------------------------------------------------------------------------------------

The above-mentioned results showed that cZNF609 mainly regulated Müller cell and RGC function. We then studied the mechanistic aspects and functional significance of cZNF609 expression change in vitro. cZNF609 shRNA transfection significantly decreased cZNF609 expression in Müller cells (**Figure [3](#F3){ref-type="fig"}A**). MTT and Ki67 staining assays showed that cZNF609 silencing significantly decreased Müller cell viability and proliferation (**Figure [3](#F3){ref-type="fig"}B-C**). cZNF609 shRNA transfection significantly decreased cZNF609 expression in primary RGCs (**Figure [S3](#SM0){ref-type="supplementary-material"}A**). However, cZNF609 silencing did not affect RGC viability and proliferation (Figu**re S3B-C**). We also used an in vitro RGC-Müller cell co-culture system to determine whether cZNF609 silencing in Müller cells had an indirect effect on RGC function. Mechanisms involved in RGC damage in glaucoma mainly include oxidative injury and glutamate toxicity [@B27], [@B28]. PI staining revealed that cZNF609 silencing in Müller cells obviously attenuated the pro-apoptotic effect of Müller cells on RGCs in response to H~2~O~2~ or glutamate toxicity (**Figure [3](#F3){ref-type="fig"}D** and **Figure [S3](#SM0){ref-type="supplementary-material"}D**). Collectively, these results suggest that cZNF609 directly regulates Müller cell function but indirectly regulates RGC function in vitro.

cZNF609 silencing regulates retinal glial activation *in vivo*
--------------------------------------------------------------

Retinal glia cells have the capability to dedifferentiate and reenter the proliferation cycle under stress conditions [@B24]. We thus determined whether cZNF609 silencing affected the regenerative ability of retinal glial cells in vivo. We labeled the proliferating retinal cells by PCNA staining. Injection of cZNF609 shRNA significantly decreased the number of PCNA-positive cells in EVL- or microbead injection-induced glaucomatous retinas. PCNA-stained cells also overlapped with glutamine synthetase (GS) staining (**Figure [4](#F4){ref-type="fig"}A** and **Figure [S4](#SM0){ref-type="supplementary-material"}A**), suggesting that cZNF609 silencing affects retinal glial proliferation. The reactivation of stem and progenitor properties of glial cells further prompted us to determine the effect of cZNF609 silencing on the expression of progenitor markers such as Nestin [@B24]. cZNF609 silencing significantly decreased the expression of Nestin in EVL- or microbead injection-induced glaucomatous retinas (**Figure [4](#F4){ref-type="fig"}B** and **Figure [S4](#SM0){ref-type="supplementary-material"}B**).

cZNF609-miR-615-METRN is involved in regulating Müller cell function
--------------------------------------------------------------------

In our previous study, we revealed that cZNF609 regulates endothelial cell function by acting as a miR-615 sponge [@B22]. In Müller cells, RNA pull-down assays showed that cZNF609 was enriched in the miR-615-captured fraction compared to the negative control, biotinylated miR-335 (**Figure [5](#F5){ref-type="fig"}A**). Moreover, miR-615 was enriched in the cZNF609-captured fraction compared to the negative control, biotinylated cZNF532 (**Figure [5](#F5){ref-type="fig"}B**).

We then determined the role of miR-615 in Müller cells. miR-615 mimic transfection significantly decreased Müller cell viability and proliferation (**Figure [5](#F5){ref-type="fig"}C-D**). Müller cell and RGC co-culture and PI staining assays showed that miR-615 mimic transfection in Müller cells obviously attenuated the harmful effect of Müller cells on RGC function in response to H~2~O~2~ or glutamate treatment, which could mimic cZNF609 silencing (**Figure [5](#F5){ref-type="fig"}E-F**).

We them employed the Targetscan database to predict the target gene of miR-615. One of the candidate genes, meteorin (METRN), aroused our interest due to its role in cell differentiation and proliferation [@B29], [@B30]. miR-615 mimic transfection significantly reduced METRN expression (**Figure [S5](#SM0){ref-type="supplementary-material"}A**). Luciferase reporter assay further verified the direct regulation of miR-615 on METRN expression (**Figure [S5](#SM0){ref-type="supplementary-material"}B**). We also revealed that cZNF609 silencing significantly reduced METRN expression (**Figure [S5](#SM0){ref-type="supplementary-material"}C**). Moreover, cZNF609 silencing-induced inhibition of glial cell proliferation could be partially reversed by METRN overexpression (**Figure [S5](#SM0){ref-type="supplementary-material"}D**).

Discussion
==========

Glaucoma is a neurodegenerative disease with complex etiology and pathogenesis. Neuroprotection is a promising therapeutic method for preventing, retarding, and reversing retinal neurodegenation induced by glaucoma [@B7], [@B31]. In this study, we show that cZNF609 silencing inhibits retinal reactive gliosis, glial cell activation, and contributes to RGC survival in glaucoma. cZNF609 silencing directly regulates Müller cell function but indirectly regulates RGC function in vitro. cZNF609 acts as miR-615 sponge to sequester and inhibit miR-615 activity, which leads to increased METRN. This study provides novel insights for understanding the pathogenesis of retinal neurodegeneration.

Under the normal condition, retinal glial cells support the functions of neurons via several mechanisms, including the removal of extracellular glutamate and synthesis of growth factors and metabolites [@B7]. Retinal glial cells are activated during retinal neurodegeneration in glaucoma [@B32]. GFAP, a marker of Müller cells, appears to be significantly elevated at the early stage of glaucoma and before widespread RGC apoptosis. Retinal glial activation leads to decreased biosynthesis of glutamate receptors [@B33]. Moreover, activated glial cells exacerbate neuronal damage through the release of cytokines, reactive oxygen species, or nitric oxide [@B34], [@B35]. These effects may lead to RGC apoptosis. cZNF609 is significantly up-regulated in retinal neurodegeneration induced by glaucoma. Increased cZNF609 expression could contribute to retinal reactive gliosis and glial cell activation. We speculate that cZNF609 silencing could reduce Müller cell-induced harmful effects on RGCs, which in turn facilitate RGC survival in glaucoma.

Müller glial cells greatly outnumber RGCs in the retina and have intimate relationships with RGCs [@B36]. Müller glia contribute to several RGC functions, including synapse formation and plasticity, redox metabolism, and homeostasis of neurotransmitters and ions [@B37]. H~2~O~2~ or glutamate treatment would alter the cytosecretion component of Müller cells. The addition of Müller cell culture medium increased the number of apoptotic RGCs. cZNF609 silencing in Müller cells obviously attenuated this harmful effect. Thus, cZNF609-mediated signaling is involved in RGC-glia interaction, and its dysregulation would affect the progression of retinal neurodegeneration induced by glaucoma.

We also investigated the mechanism of cZNF609-regulated retinal neurodegeneration. circular RNAs play their roles through several molecular mechanisms such as acting as miRNA sponges, RNA-binding protein sequestering agents, nuclear transcriptional regulators, or by showing translation potentials [@B15], [@B21], [@B38]. As for cZNF609, previous studies have revealed that it mainly plays its role by acting as a miRNA sponge. cZNF609 takes part in the onset of Hirschsprung disease (HSCR) through crosstalk with AKT3 by competing for binding with miR-150-5p [@B20]. cZNF609 acts as an endogenous miR-615-5p sponge to sequester and inhibit miR-615-5p activity in endothelial cells [@B22]. In Müller cells, increased cZNF609 may sponge and sequester miR-615 in response to oxidative stress or glutamate excitotoxicity, releasing miR-615-mediated repressive effects on Müller cell function. A slight change in cZNF609 level may alter the balance of cZNF609/miR-615/target genes in the regulatory network.

Meteorin (METRN) is a secreted protein that has been previously reported to control neuritogenesis, angiogenesis, and gliogenesis. Meteorin plays important roles in both glial cell differentiation and axonal network formation during neurogenesis [@B29], [@B39]. Meteorin also contributes to the formation of GFAP-positive glia via activation of the JAK-STAT3 pathway [@B30]. METRN overexpression would partially reverse cZNF609 silencing-mediated inhibitory effects on Müller cell proliferation. During retinal neurodegeneration, cZNF609 overexpression becomes the sink of miR-615, and releases the miR-615-mediated inhibitory effect on METRN expression. METRN upregulation would contribute to Müller cell activation. This regulatory mechanism would provide novel insights into retinal neurodegeneration.

Conclusions
===========

This study reveals that cZNF609 is an important regulator of retinal neurodegeneration. cZNF609 silencing inhibits retinal reactive gliosis and glial cell activation, and facilitates RGC survival. cZNF609 regulates retinal neurodegeneration through a regulatory network, which is composed of cZNF609, miR-615, and METRN. This study provides a promising target for treating retinal neurodegenerative diseases.
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![**cZNF609 expression is significantly up-regulated during retinal neurodegeneration. (A)** The amplified product of cZNF609 using total RNAs from rat retinas was sent for Sanger sequencing. **(B)** Total RNAs from rat retinas were digested with RNase R followed by qRT-PCR detection of cZNF609 expression. ZNF609 mRNA was detected as the RNase R-sensitive control (n=4). **(C)** IOP levels in the sham eyes or EVL eyes are shown (n=5). **(D)** qRT-PCRs were conducted to detect cZNF609 expression in the retinas of rats after EVL at the indicated time points (n=5 animals per group). **(E)** IOP levels in the sham eyes (saline injection) and microbead injection (injected eyes) are shown (n=5). **(F)** qRT-PCRs were conducted to detect cZNF609 expression in the retinas of rats after microbead injection at the indicated time points (n=5). **(G)** qRT-PCRs were conducted to detect cZNF609 expression in the aqueous humor of glaucomatous rats induced by EVL or microbead injection (n=5).](thnov08p3408g001){#F1}

![**cZNF609 silencing regulates retinal reactive gliosis and RGC survival in vivo. (A)** The rat retinas were injected with scrambled shRNA (Scr), cZNF609 shRNA-1, cZNF609 shRNA-2, cZNF609 shRNA-3, or left untreated for 48 h. qRT-PCRs were conducted to detect cZNF609 expression (n=4, \**P*\<0.05 versus Ctrl). **(B-C)** Three months after EVL, retinal slices were stained with GFAP (B) and TUJ1 (C) to detect retinal reactive gliosis and RGC survival (n=5, \**P*\<0.05 versus Scr shRNA). Scale bar, 100 µm. GCL: ganglion cell layer; INL: inner nuclear layer; ONL: outer nuclear layer.](thnov08p3408g002){#F2}

![**cZNF609 silencing directly regulates Müller cell function but indirectly regulates RGC function in vitro. (A)** Müller cells were transfected with scrambled shRNA (Scr), cZNF609 shRNA1, cZNF609 shRNA2, or left untreated (Ctrl) for 24 h. qRT-PCRs were conducted to detect cZNF609 expression (n=4, \**P*\<0.05 versus Ctrl). **(B)** The viability of Müller cells was detected by the MTT method. The data is shown as relative change compared with the Ctrl group (n=4, \**P*\<0.05 versus Ctrl). **(C)** Ki67 staining was conducted to detect the proliferation of Müller cells (n=4, \**P*\<0.05 versus Ctrl group). Scale bar: 20 μm. **(D)** RGCs were co-cultured with or without wild-type Müller cells, Scr shRNA-transfected Müller cells, cZNF609 shRNA1-transfected Müller cells, or cZNF609 shRNA2-transfected Müller cells, and then treated with H~2~O~2~ (100 μm) for 24 h. PI staining and quantitative analysis was conducted to detect apoptotic RGCs. \**P*\<0.05 versus Müller cell group.](thnov08p3408g003){#F3}

![**cZNF609 silencing affects retinal glial cell activation in vivo. (A)** Three months after EVL, retinal slices were stained with PCNA and GS antibody to label retinal glial cell proliferation. **(B)** Retinal slices were stained with a progenitor marker, Nestin, to detect the effect of cZNF609 silencing on the reactivation of stem and progenitor properties of glial cells. Scale bar, 100 µm. GCL: ganglion cell layer; INL: inner nuclear layer; ONL: outer nuclear layer; \**P*\<0.05 versus Scr shRNA.](thnov08p3408g004){#F4}

![**cZNF609-miR-615-METRN is involved in regulating Müller cell function. (A)** The 3\'-end biotinylated miR-615 or miR-335 (negative control) duplexes were transfected into Müller cells. After the streptavidin capture, the amount of cZNF609 and cZNF532 (negative control) in the input and bound fraction was detected by qRT-PCRs. **(B)** The 3\'-end biotinylated cZNF609 or cZNF532 was transfected into Müller cells. After the streptavidin capture, the amount of miR-615 and miR-335 in the input and bound fraction was detected by qRT-PCRs. **(C-D)** Müller cells were transfected with scrambled miRNA mimic (Scr), miR-615 mimic, or left untreated for 24 h. MTT assays (C) and Ki67 staining (D) were conducted to detect cell viability and proliferation (n=4, \**P*\<0.05 versus Ctrl group). Scale bar: 20 μm. **(E-F)** RGCs were co-cultured with or without wild-type Müller cells, miR-615 mimic-transfected Müller cells, or Scr miRNA mimic-transfected Müller cells, and then treated with 100 μm H~2~O~2~ (E) or 3 mM glutamate (F) for 24 h. PI staining and quantitative analysis were conducted to detect the apoptotic RGCs. \**P*\<0.05 versus Müller cell group.](thnov08p3408g005){#F5}
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